

Table 2 Associated symptom outcomes and confidence in evidence

Outcome	High confidence (more likely than placebo)	Moderate confidence (probably more likely than placebo)	Low confidence (possibly more likely than placebo)	Moderate confidence (probably no more likely than placebo)	Low confidence (possibly no more likely than placebo)	Very low confidence (insufficient evidence)
Relief of nausea at 2 hours				Sumatriptan NS 5 mg Sumatriptan NS 20 mg Sumatriptan/ naproxen OT 85/500 mg	Eletriptan OT 40 mg	Ibuprofen OS 7.5–10 mg/kg Sumatriptan NS 10 mg Sumatriptan/ naproxen OT 10/60 mg Sumatriptan/ naproxen OT 30/180 mg Rizatriptan ODT 5 or 10 mg
Relief of vomiting at 2 hours				Sumatriptan NS 5 mg Sumatriptan NS 20 mg	Sumatriptan NS 10 mg Rizatriptan ODT 5 or 10 mg	
Relief of photophobia at 30 minutes		Zolmitriptan NS 5 mg				
Relief of photophobia at 2 hours		Sumatriptan/ naproxen OT 10/60 mg Sumatriptan/ naproxen OT 85/500 mg	Zolmitriptan NS 5 mg		Eletriptan OT 40 mg	Sumatriptan NS 10 mg Sumatriptan/ naproxen OT 30/180 mg Rizatriptan ODT 5 or 10 mg
Relief of phonophobia at 30 minutes		Zolmitriptan NS 5 mg				
Relief of phonophobia at 2 hours		Sumatriptan/ naproxen OT 10/60 mg Sumatriptan/ naproxen OT 85/500 mg	Sumatriptan NS 5 mg Sumatriptan NS 20 mg Sumatriptan/ naproxen OT 30/180 mg	Rizatriptan ODT 5 or 10 mg	Eletriptan OT 40 mg	Sumatriptan NS 10 mg Zolmitriptan NS 5 mg

Abbreviations: NS = nasal spray; ODT = oral disintegrating tablet; OS = oral solution; OT = oral tablet.

- Sumatriptan NS 20 mg (RR 1.27; 95% CI 1.09–1.49; 1 Class I⁴ and 2 Class II studies^{6,7})

Adolescents receiving zolmitriptan NS 5 mg are possibly more likely than those receiving placebo to have a headache pain response at 1 hour (RR 1.34; 95% CI 1.05–1.71; 1 Class II study⁸).

Very low confidence in the evidence

There is insufficient evidence to determine whether children and adolescents receiving the following treatments are more or less likely than those receiving placebo to have a headache pain response at 1 hour:

- Sumatriptan OT 25 mg (RR 0.49; 95% CI 0.16–1.48; 1 Class I study⁵)
- Sumatriptan OT 50 mg (RR 0.39; 95% CI 0.13–1.19; 1 Class I study⁵)

Outcome: Pain response at 2 hours

Moderate confidence in the evidence

Children and adolescents receiving 5 or 10 mg of rizatriptan oral disintegrating tablets (ODT) are probably no more likely than those receiving placebo to have a headache pain response at 2 hours (RR 1.07; 95% CI 0.97–1.17; 3 Class II studies^{9–11}).

Low confidence in the evidence

Children and adolescents receiving the following treatments are possibly more likely than those receiving placebo to have a headache pain response at 2 hours:

- Ibuprofen oral solution (OS) 7.5–10 mg/kg (RR 1.54; 95% CI 1.18–2.01; 1 Class II¹² and 1 Class III¹³ study)
- Acetaminophen OS 15 mg/kg (RR 1.46; 95% CI 1.02–2.09; 1 Class II study¹²)
- Sumatriptan NS 20 mg (RR 1.32; 95% CI 1.04–1.68; 1 Class I⁴ and 2 Class II^{6,7} studies)